Rusfertide acetate is under clinical development by Protagonist Therapeutics and currently in Phase III for Polycythemia Vera. According to GlobalData, Phase III drugs for Polycythemia Vera have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Rusfertide acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rusfertide acetate overview
PTG-300 is under development for the treatment of iron overload related indications including polycythemia vera. It is a hepcidin mimetic. It is injected through subcutaneous route. The drug candidate is developed based on Vectrix technology platform.
It was also under development for beta-thalassemia, hereditary hemochromatosis and myelodysplastic syndromes.
Protagonist Therapeutics overview
Protagonist Therapeutics (Protagonist) is a biopharmaceutical company. It specializes in developing peptide-based new chemical entities, with its leading candidates, Rusfertide and JNJ-2113, in advanced clinical stages. Rusfertide (PTG-300) is an injectable hepcidin mimetic for polycythemia vera, enhancing iron regulation and managing hematocrit levels. JNJ-2113, an oral interleukin-23 receptor antagonist targets gastrointestinal and systemic conditions, with several Phase 3 trials underway for plaque psoriasis and a Phase 2b study for ulcerative colitis. Protagonist is developing PN-943 for inflammatory bowel disease and exploring new oral hepcidin mimetics and IL-17 peptide antagonists for conditions such as hidradenitis suppurativa, spondyloarthritis, plaque psoriasis and psoriatic arthritis. Protagonist is headquartered in Newark, California, the US.
For a complete picture of Rusfertide acetate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
